Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2024 · 10-Q
Revenue$2.73M$2.73M−18.0% vs Q2 2023 Net Income-$1.48M-$1.48MN/M vs Q2 2023 EPS Diluted-$5.75-$5.75N/M vs Q2 2023 Gross Profit$990,000−35.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,231,000N/M Free Cash Flowderived-$1,233,000N/M Margins · derivedGross margin36.3%−9.9 pt vs Q2 2023
Operating margin-44.2%−22.3 pt vs Q2 2023
Net margin-54.3%−23.8 pt vs Q2 2023
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end